Novartis to implement additional job cuts: Vasella to WSJ

Share this article:
Novartis CEO Daniel Vasella
Novartis CEO Daniel Vasella

Novartis is planning to cut around 2,500 jobs globally, or 2.5% of its workforce, as part of a plan to cut costs and boost growth, Novartis CEO Daniel Vasella told The Wall Street Journal Europe in an interview this week.

The latest job cuts come on top of the 1,260 positions Novartis is eliminating in its US pharmaceutical division after a year of disappointing earnings and product setbacks.
"We have taken the opportunity given the short-term down-cycle in our pharmaceuticals business to initiate this project," Vasella told The Journal. "This will simplify our organization and redesign the way we operate."

The restructuring should be implemented during 2008 and 2009 and is aimed at creating annual pretax cost savings of about $1.6 billion in 2010, Novartis said.

Staff cuts should be achieved through staff fluctuation, vacancy management and social programs, The Journal reported.

Novartis also said it will streamline its divisions, improve its sales force organization and start to expand its presence in emerging markets such as Northern and Sub-Saharan Africa, Central Asia and parts of Southeast Asia. Novartis experienced tough losses on a number of key products.

Zelnorm sales fell 80% after the company was forced to pull the irritable bowel treatment from the market in March due to safety concerns. And generic competition caught up Lamisil, Lotrel and Famivir. A top pipeline prospect, type 2 diabetes drug Galvus, was delayed at the FDA.

Share this article:
You must be a registered member of MMM to post a comment.


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...